BioNTech Plans to Initiate the Clinical Study of Malaria and Tuberculosis Vaccines in 2022
Pfizer and BioNTech Report Results of COVID-19 Vaccine Booster in P-III Trial for the Treatment of COVID-19
Shots:
- BioNTech unveils the plan to develop the first mRNA-based vaccine to prevent malaria with anticipated initiation of the clinical study by the end of 2022
- The company intends to set up a large vaccine production hub in Africa with the help of local partners and transfer its mRNA technology to Africa. These efforts of the company are supported by WHO and the Africa CDC
- BioNTech’s Malaria project is part of the ‘eradicateMalaria’ initiative, led by the kENUP Foundation, to hasten the eradication of Malaria. Additionally, the company is planning to start clinical trials for tuberculosis vaccines in 2022, two yrs. after the initiation of the program
Click here to read full press release/ article | Ref: GLOBE NEWSWIRE | Image: BioNTech